Using protein microarray as a diagnostic assay for non-small cell lung cancer.

PubWeight™: 1.13‹?› | Rank: Top 10%

🔗 View Article (PMC 2718416)

Published in Am J Respir Crit Care Med on August 18, 2005

Authors

Li Zhong1, Giovanna E Hidalgo, Arnold J Stromberg, Nada H Khattar, James R Jett, Edward A Hirschowitz

Author Affiliations

1: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Kentucky, Chandler Medical Center, K528 Kentucky Clinic, 740 S. Limestone, Lexington, Kentucky 40536, USA. lzhon2@uky.edu

Articles citing this

Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One (2010) 1.66

The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila) (2012) 1.49

Glycoarrays with engineered phages displaying structurally diverse oligosaccharides enable high-throughput detection of glycan-protein interactions. Biotechnol J (2014) 1.38

Autoantibody approach for serum-based detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.35

Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res (2008) 1.13

Use of a single-chain antibody library for ovarian cancer biomarker discovery. Mol Cell Proteomics (2010) 1.00

Immunogenicity of autoantigens. BMC Genomics (2011) 0.97

Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer (2010) 0.94

Identification of lung cancer with high sensitivity and specificity by blood testing. Respir Res (2010) 0.91

Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer. Cancer Biol Ther (2010) 0.89

Advances in proteomic strategies toward the early detection of lung cancer. Proc Am Thorac Soc (2011) 0.87

Lung cancer screening: history, current perspectives, and future directions. Arch Med Sci (2015) 0.86

Improving seroreactivity-based detection of glioma. Neoplasia (2009) 0.86

Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts. PLoS One (2014) 0.86

Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics (2011) 0.86

High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J (2009) 0.84

Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. OMICS (2011) 0.83

Identification of novel autoantibodies for detection of malignant mesothelioma. PLoS One (2013) 0.77

Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. Onco Targets Ther (2013) 0.77

Usage of cancer associated autoantibodies in the detection of disease. Cancer Biomark (2010) 0.76

Multianalyte tests for the early detection of cancer: speedbumps and barriers. Biomark Insights (2007) 0.75

Protein Array-based Approaches for Biomarker Discovery in Cancer. Genomics Proteomics Bioinformatics (2017) 0.75

Articles cited by this

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06

Lung cancer. Lancet (2000) 3.93

Disease proteomics. Nature (2003) 3.36

Sec15 is an effector for the Rab11 GTPase in mammalian cells. J Biol Chem (2004) 2.24

Lung cancer screening: a different paradigm. Am J Respir Crit Care Med (2003) 2.08

Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol (2004) 1.88

An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A (2001) 1.85

Screening for lung cancer using low dose CT scanning. Thorax (2004) 1.64

Immunity to oncogenic proteins. Immunol Rev (1995) 1.58

Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis (2001) 1.55

Genomic organization of the human PMS2 gene family. Genomics (1995) 1.50

Screening for lung cancer: a review of the current literature. Chest (2003) 1.46

The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids (2004) 1.44

Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer (2003) 1.41

Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res (2001) 1.39

Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res (1999) 1.38

Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer (2001) 1.37

Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res (1998) 1.27

Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res (2001) 1.24

Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol (2005) 1.19

Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer (2002) 1.11

Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene (2005) 1.10

Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer (1992) 1.08

Clinical tumour markers in lung cancer. Eur J Cancer Prev (1995) 1.05

Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics (2004) 1.05

Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res (2000) 1.04

Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res (2001) 1.04

Identification and characterization of a nucleolar phosphoprotein, Nopp140, as a transcription factor. Mol Cell Biol (1997) 1.01

Lung tumor markers of cytokeratin origin: an overview. Lung Cancer (2001) 1.01

Recruitment of focal adhesion kinase and paxillin to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase activation. BMC Cancer (2004) 0.99

Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol (2001) 0.99

Harnessing immunity for cancer marker discovery. Nat Biotechnol (2003) 0.99

Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res (1996) 0.99

Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma (1999) 0.96

Serum tumour markers in lung cancer: history, biology and clinical applications. Eur Respir J (1994) 0.95

Toward a more complete recognition of immunoreactive antigens in squamous cell lung carcinoma. Int J Cancer (2002) 0.91

Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol Carcinog (2004) 0.90

Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma. Cancer (1986) 0.86

[Relationship of the expression of CD44v6 and paxillin to the prognosis of non-small cell lung carcinoma]. Sichuan Da Xue Xue Bao Yi Xue Ban (2003) 0.83

Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis. Chest (1990) 0.82

Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep (2004) 0.80

Clinical evaluation of five tumor marker assay in patients with lung cancer. Anticancer Res (1991) 0.77

Articles by these authors

Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology (2005) 9.83

Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71

Computed tomography screening and lung cancer outcomes. JAMA (2007) 8.01

Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med (2002) 5.10

Lung cancer screening with CT: Mayo Clinic experience. Radiology (2003) 4.72

The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68

CT screening for lung cancer: five-year prospective experience. Radiology (2005) 4.33

The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci (2008) 4.28

Non-small-cell lung cancer. Lancet (2011) 3.45

Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology (2007) 3.44

Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest (2010) 3.13

Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol (2012) 3.10

Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinformatics (2003) 2.52

5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest (2009) 2.45

The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32

Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol (2004) 2.18

Advances in chemotherapy of non-small cell lung cancer. Chest (2006) 2.00

Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol (2006) 1.85

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.81

Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg (2004) 1.77

Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol (2006) 1.75

Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol (2010) 1.71

Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg (2004) 1.67

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer (2010) 1.63

Global identification of targets of the Arabidopsis MADS domain protein AGAMOUS-Like15. Plant Cell (2009) 1.63

A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest (2006) 1.59

Molecular basis of age-associated cytokine dysregulation in LPS-stimulated macrophages. J Leukoc Biol (2006) 1.59

Change in smoking status after spiral chest computed tomography scan screening. Cancer (2003) 1.55

Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2002) 1.55

miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol (2010) 1.54

Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer (2010) 1.53

Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer (2005) 1.51

Assessment of mitotic rate reporting in melanoma. Am J Surg (2012) 1.47

Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes. RNA (2009) 1.45

Enhanced disease susceptibility 1 and salicylic acid act redundantly to regulate resistance gene-mediated signaling. PLoS Genet (2009) 1.44

Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.43

Endoscopic evaluation of arytenoid function and epiglottic structure in Thoroughbred yearlings and association with racing performance at two to four years of age: 2,954 cases (1998-2001). J Am Vet Med Assoc (2010) 1.38

Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc Natl Acad Sci U S A (2014) 1.37

Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer (2007) 1.36

Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32

Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol (2005) 1.27

A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer (2006) 1.26

Effectiveness of smoking cessation self-help materials in a lung cancer screening population. Lung Cancer (2004) 1.19

Quadratic regression analysis for gene discovery and pattern recognition for non-cyclic short time-course microarray experiments. BMC Bioinformatics (2005) 1.19

Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest (2007) 1.19

Leptin regulates olfactory-mediated behavior in ob/ob mice. Physiol Behav (2006) 1.17

Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg (2005) 1.17

The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest (2007) 1.16

Emx2 stimulates odorant receptor gene expression. Chem Senses (2008) 1.16

Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer (2009) 1.15

A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer (2007) 1.14

Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability. Oncogene (2002) 1.12

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol (2012) 1.12

Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. J Thorac Cardiovasc Surg (2012) 1.11

Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med (2005) 1.11

Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg (2005) 1.09

Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol (2009) 1.08

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol (2005) 1.07

Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics (2004) 1.05

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res (2007) 1.05

Individual microRNAs (miRNAs) display distinct mRNA targeting "rules". RNA Biol (2010) 1.04

Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. Cancer Epidemiol Biomarkers Prev (2012) 1.04

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer (2007) 1.03

Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res (2005) 1.03

Large-scale gene profiling of the liver in a mouse model of chronic, intragastric ethanol infusion. J Hepatol (2004) 1.02

Analysis of oligonucleotide array experiments with repeated measures using mixed models. BMC Bioinformatics (2004) 1.01

Statistics and bioinformatics in nutritional sciences: analysis of complex data in the era of systems biology. J Nutr Biochem (2010) 1.00

Linear methods for analysis and quality control of relative expression ratios from quantitative real-time polymerase chain reaction experiments. ScientificWorldJournal (2011) 0.97

Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann Surg (2010) 0.96

The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer (2007) 0.96

Gene expression patterns specific to the regenerating limb of the Mexican axolotl. Biol Open (2012) 0.95

Characterization of the human polymeric immunoglobulin receptor (PIGR) 3'UTR and differential expression of PIGR mRNA during colon tumorigenesis. J Biomed Sci (2003) 0.95

Coregulated expression of loline alkaloid-biosynthesis genes in Neotyphodium uncinatum cultures. Fungal Genet Biol (2009) 0.95

Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc (2008) 0.94

Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc (2003) 0.94

Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference. Chest (2005) 0.94

Genomics of mature and immature olfactory sensory neurons. J Comp Neurol (2012) 0.94

Gene expression profile of mouse white adipose tissue during inflammatory stress: age-dependent upregulation of major procoagulant factors. Aging Cell (2013) 0.93

Temporal profiling of gene expression during neurogenesis and remodeling in the olfactory epithelium at short intervals after target ablation. J Neurosci Res (2005) 0.93

Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol (2005) 0.93

Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol (2008) 0.92

Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer. Cancer Lett (2004) 0.92

Prognostic significance of tumor infiltrating lymphocytes in melanoma. Am Surg (2011) 0.92

Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer (2005) 0.92

Antibodies to HSP70 and HSP90 in serum in non-small cell lung cancer patients. Cancer Detect Prev (2003) 0.92

Second primary melanomas: incidence and outcome. Am Surg (2010) 0.92

Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis (2007) 0.91

Transcriptional profiling differences for articular cartilage and repair tissue in equine joint surface lesions. BMC Med Genomics (2009) 0.91

Using common table expressions to build a scalable Boolean query generator for clinical data warehouses. IEEE J Biomed Health Inform (2014) 0.91

Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker. Am J Surg (2011) 0.90

An Official American Thoracic Society Research Statement: A Research Framework for Pulmonary Nodule Evaluation and Management. Am J Respir Crit Care Med (2015) 0.90

Computed tomographic screening for lung cancer: home run or foul ball? Mayo Clin Proc (2003) 0.90

Plasma PGE-2 levels and altered cytokine profiles in adherent peripheral blood mononuclear cells in non-small cell lung cancer (NSCLC). Mol Cancer (2002) 0.89